Abstract
Combined warfarin–aspirin therapy is currently used in about 1 million patients in North America for the long-term primary and secondary prevention of atherothrombotic and thromboembolic diseases. Despite a potentially complementary action of anticoagulant and antiplatelet drugs on different components of the thrombotic pathway, their combined use, typically with warfarin and aspirin, is not based in many cases on compelling evidence of a net therapeutic benefit. In the real-world management of patients, clinicians should combine the best available evidence with clinical judgment, considering also that, in most clinical scenarios, clinical practice guidelines may not provide strong or proscriptive recommendations for patients who should (and should not) receive combined aspirin–warfarin therapy. The objectives of this review are to describe the characteristics of patients who are receiving combined warfarin–aspirin therapy, to summarize the evidence for the therapeutic benefit and harm of combined warfarin–aspirin, and to provide practical guidelines as to which patients should (or should not) receive such treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Johnson SG, Witt DM, Eddy TR, Delate T (2007) Warfarin and antiplatelet combination use among commercially insured patients enrolled in a anticoagulation management service. Chest 131:1500–1507
Go AS, Hylek EM, Phillips JA, Chang YC, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375
National Heart, Lung, and Blood Institute (2007) Morbidity and mortality: 2007 chart book on cardiovascular, lung, and blood disease. Bethesda (MD). http://www.nhlbi.nih.gov/resources/docs/cht-book.htm
Dentali F, Douketis JD, Lim W, Crowther M (2007) Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease. Arch Intern Med 167:117–124
Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360:109–113
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969–974
Flacker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL (2006) Risk and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 152:967–973
Johnson SG, Rogers K, Delate T, Witt DM (2008) Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 133:948–954
Linkins L, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med 139:893–900
Douketis J, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J (2006) Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin. Arch Intern Med 166:853–859
Becker RC, Meade TW, Berger PB, Ezekowitz M, O’Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA (2008) The primary and secondary prevention of coronary artery disease. American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:776S–814S
Fuster V, Rydén LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation––executive summary. Circulation 114:700–752
Salem DN, O’Gara PT, Madias C, Pauker SG (2008) Valvular and structural heart disease. American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:593S–629S
Bonow RO, Carabello BA, Chatterjee K et al (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease––executive summary. Circulation 114:450–527
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Donadini, M.P., Douketis, J.D. Combined warfarin–aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it?. J Thromb Thrombolysis 29, 208–213 (2010). https://doi.org/10.1007/s11239-009-0413-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-009-0413-4